Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but ...

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption.

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...

Number 4: Regulatory experts and representatives from some of the top biosimilar manufacturers emphasized the importance of ...

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...